

Novartis India Limited

Inspire – BKC, 7th Floor, Bandra Kurla Complex Bandra East Mumbai 400 051

Tel: 0091 22 50243000 Website: www.novartis.in CIN – L24200MH1947PLC006104 Email: india.investors@novartis.com

September 30, 2025

To, The Secretary BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

Scrip code: 500672

Sub.: Intimation of the meeting of Board of Directors of Novartis India Limited ('the Company') and the Closure of Trading Window.

Dear Sir/ Madam,

This is to inform that pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of the Board of Directors of the Company is scheduled to be held on **Tuesday**, **October 28, 2025**, to *inter alia*, consider and approve the **Unaudited Financial Results and the Limited Review Report** of the Company for the quarter and half year ended September 30, 2025.

In this connection, please note that pursuant to the 'Code of Conduct to regulate, monitor and report share trading by Designated Persons and their immediate relatives' ('Code') read with the applicable provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the Trading Window for dealing in shares of the Company by Designated Persons / Insiders / Connected Persons and their immediate relatives will be closed **with effect from Wednesday, October 01, 2025**. The Trading Window will open 48 hours after the said financial results are declared to the Stock Exchange.

You are requested to take note of the above information.

Thanking You.

Yours Sincerely,

For Novartis India Limited

CHANDNI BHUPENDRA MARU Digitally signed by CHANDNI BHUPENDRA MARU Date: 2025.09.30 12:54:22 +05'30'

Chandni Maru
Company Secretary and Compliance Officer
M. No.- A60291